Joseph Thome
Stock Analyst at TD Cowen
(1.72)
# 3,404
Out of 5,132 analysts
19
Total ratings
50%
Success rate
-2.46%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Thome
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTCT PTC Therapeutics | Maintains: Hold | $50 → $63 | $69.45 | -9.29% | 3 | Nov 5, 2025 | |
| ARDX Ardelyx | Maintains: Buy | $9 → $10 | $6.87 | +45.56% | 1 | Oct 31, 2025 | |
| MIRM Mirum Pharmaceuticals | Initiates: Buy | $95 | $103.10 | -7.86% | 1 | Sep 24, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Buy | n/a | $77.90 | - | 1 | May 13, 2025 | |
| VRDN Viridian Therapeutics | Initiates: Buy | n/a | $27.90 | - | 1 | Nov 25, 2024 | |
| UTHR United Therapeutics | Maintains: Buy | $350 → $400 | $473.66 | -15.55% | 2 | Oct 21, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | n/a | $27.93 | - | 1 | Jul 2, 2024 | |
| ALKS Alkermes | Initiates: Buy | $34 | $33.16 | +2.53% | 1 | Jun 17, 2024 | |
| PRME Prime Medicine | Initiates: Buy | n/a | $3.30 | - | 1 | Apr 8, 2024 | |
| MGX Metagenomi Therapeutics | Initiates: Outperform | n/a | $1.46 | - | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $41.48 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.63 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $130 | $181.21 | -28.26% | 2 | Jun 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $11.87 | - | 1 | Jan 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $10.88 | - | 1 | Nov 23, 2021 |
PTC Therapeutics
Nov 5, 2025
Maintains: Hold
Price Target: $50 → $63
Current: $69.45
Upside: -9.29%
Ardelyx
Oct 31, 2025
Maintains: Buy
Price Target: $9 → $10
Current: $6.87
Upside: +45.56%
Mirum Pharmaceuticals
Sep 24, 2025
Initiates: Buy
Price Target: $95
Current: $103.10
Upside: -7.86%
Bright Minds Biosciences
May 13, 2025
Initiates: Buy
Price Target: n/a
Current: $77.90
Upside: -
Viridian Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: n/a
Current: $27.90
Upside: -
United Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $350 → $400
Current: $473.66
Upside: -15.55%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: n/a
Current: $27.93
Upside: -
Alkermes
Jun 17, 2024
Initiates: Buy
Price Target: $34
Current: $33.16
Upside: +2.53%
Prime Medicine
Apr 8, 2024
Initiates: Buy
Price Target: n/a
Current: $3.30
Upside: -
Metagenomi Therapeutics
Mar 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $1.46
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $41.48
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $1.63
Upside: -
Jun 29, 2022
Maintains: Outperform
Price Target: $120 → $130
Current: $181.21
Upside: -28.26%
Jan 31, 2022
Initiates: Outperform
Price Target: n/a
Current: $11.87
Upside: -
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $10.88
Upside: -